Loading stock…

bioMérieux S.A. (BIM) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

BIMbioMérieux S.A.

Revenue FY25$4.8B

GROWTH RATING↗

WEAK29 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+8%6

Revenue, next 1Y-3%2

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+4%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+25%8

EPS growth, FY27E+8%6

EPS growth, FY28E+8%6

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow in step with sales (EPS about 8%/yr vs revenue 4%/yr).

WATCH

Revenue grew 8%/yr over the last 3 years; forecasts see it cooling to 4%/yr.

Over five years revenue is set to grow 4%/yr, behind 60% of companies worldwide.4/10

WEAKNESSES

Growth is the weak spot here, trailing 71% of companies worldwide.

Revenue is set to grow 4%/yr over the next 3 years, behind most of the market.3/10

BOTTOM LINE

Margin Expander

Growth is a weak point here: a business that is slowing. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

BIMbioMérieux S.A.

Total return Current91.3%

Price return Current81.2%

MOMENTUM RATING↗

AVERAGE39 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+9%10

3-month return+13%9

YTD return-27%2

MID & LONG-TERM▾SCORE

% of 52-week high70%3

1-year return-29%2

3-year return-11%2

5-year return-15%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+9%) and over three months (+13%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-11% over three years and -15% over five), behind 70% of the market.

It's down 29% over the past year, now 30% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-27%).

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on bioMérieux. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

BIMbioMérieux S.A.

Revenue FY25$4.8B

GROWTH RATING↗

WEAK29 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+8%6

Revenue, next 1Y-3%2

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+4%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+25%8

EPS growth, FY27E+8%6

EPS growth, FY28E+8%6

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow in step with sales (EPS about 8%/yr vs revenue 4%/yr).

WATCH

Revenue grew 8%/yr over the last 3 years; forecasts see it cooling to 4%/yr.

Over five years revenue is set to grow 4%/yr, behind 60% of companies worldwide.4/10

WEAKNESSES

Growth is the weak spot here, trailing 71% of companies worldwide.

Revenue is set to grow 4%/yr over the next 3 years, behind most of the market.3/10

BOTTOM LINE

Margin Expander

Growth is a weak point here: a business that is slowing. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

BIMbioMérieux S.A.

Total return Current91.3%

Price return Current81.2%

MOMENTUM RATING↗

AVERAGE39 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+9%10

3-month return+13%9

YTD return-27%2

MID & LONG-TERM▾SCORE

% of 52-week high70%3

1-year return-29%2

3-year return-11%2

5-year return-15%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+9%) and over three months (+13%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-11% over three years and -15% over five), behind 70% of the market.

It's down 29% over the past year, now 30% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-27%).

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on bioMérieux. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

bioMérieux S.A.

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on bioMérieux. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on bioMérieux. Get the full investment case.

Premium